CANTEX to Present Four Azeliragon Abstracts at 2024 ASCO Meeting

In a recent announcement, Cantex Pharmaceuticals, Inc., located in WESTON, Fla., revealed that its innovative drug azeliragon will be highlighted in four distinct abstracts at the 2024 ASCO Annual Meeting in Chicago. Cantex Pharmaceuticals is a clinical stage company dedicated to creating breakthrough therapies for life-threatening illnesses such as cancer, which currently lack effective treatment options.

Stephen G. Marcus, M.D., the Chief Executive Officer of Cantex, emphasized the significance of the 2024 ASCO Annual Meeting as a platform to engage with top oncology researchers globally and demonstrate the advancements in clinical trials involving azeliragon for challenging cancer types.

Azeliragon, a once-daily oral medication, functions by inhibiting the receptor for advanced glycation end products (RAGE). This drug will be the focal point of several presentations at the ASCO meeting. The noteworthy abstracts include:

1. Safety and Therapeutic Effect in Metastatic Pancreatic Cancer:
- Abstract #: TPS4212
- This phase I/II open-label study aims to determine the safety and initial therapeutic efficacy of azeliragon in patients who have not responded to first-line treatments for metastatic pancreatic cancer.

2. Combination Therapy in Newly Diagnosed Glioblastoma:
- Abstract #: TPS2096
- This trial explores the CAN-201 NDG design, combining azeliragon with temozolomide and radiotherapy for patients newly diagnosed with glioblastoma. 

3. Reducing Cardiotoxicity in Early Breast Cancer:
- Abstract #: TPS619
- This study investigates the potential of azeliragon to reduce cardiotoxicity associated with cancer therapy in women with early-stage breast cancer.

4. Safety and Efficacy in Brain Metastases:
- Abstract #: TPS2093
- Known as the ADORATION study, this phase I/II trial evaluates the safety and preliminary therapeutic impact of combining azeliragon with stereotactic radiation therapy for patients with brain metastases.

Azeliragon, initially developed by vTv Therapeutics Inc. for Alzheimer’s disease, was licensed to Cantex for broader applications. Clinical trials have shown that azeliragon is well tolerated, with safety data spanning over 2000 individuals for up to 18 months. The drug has demonstrated promising preclinical data, particularly in oncology, leading to ongoing Phase II trials in pancreatic cancer, glioblastoma, brain metastasis, and breast cancer, along with a Phase 3 trial aimed at preventing acute kidney injury in hospitalized pneumonia patients.

The U.S. Food and Drug Administration (FDA) has granted azeliragon orphan drug designation for treating pancreatic cancer and glioblastoma. This designation provides Cantex with seven years of marketing exclusivity post-launch for these indications, alongside other advantages such as development assistance, clinical cost tax credits, and exemption from certain FDA fees.

Cantex Pharmaceuticals, Inc. continues its mission to develop transformative cancer therapies and other critical medical treatments. vTv Therapeutics Inc., the original developer of azeliragon, is a clinical stage biopharmaceutical company specializing in oral, small molecule drug candidates, notably cadisegliatin (TTP399), aimed at reducing hypoglycemic episodes in type 1 diabetes patients. This partnership underscores a commitment to advancing medical innovations for severe health conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!